<SEC-DOCUMENT>0001171520-22-000169.txt : 20220228
<SEC-HEADER>0001171520-22-000169.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228133337
ACCESSION NUMBER:		0001171520-22-000169
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22686943

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINGER JULIAN D.
		CENTRAL INDEX KEY:			0001628706

	FILING VALUES:
		FORM TYPE:		DFAN14A

	MAIL ADDRESS:	
		STREET 1:		2200 FLETCHER AVENUE
		STREET 2:		SUITE 501
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>eps10115.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 13.5pt Times New Roman,serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 8pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman,serif; margin: 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 6pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Amendment No. )</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">Filed by the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">Filed by a Party other than the Registrant &#9;&#9745;</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">Check the appropriate box:</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy Statement</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential, For Use of the
Commission Only (as permitted by Rule 14a-6(e)(2))</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 2pt">&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material Pursuant
to &sect;240.14a-12</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>CATALYST BIOSCIENCES, INC.</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>JDS1, LLC</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>CCUR HOLDINGS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>CIDM II, LLC</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>JULIAN D. SINGER</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>DAVID S. OROS</B></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than
the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0">Payment of Filing Fee (Check the appropriate box):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 12pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic; font-size: 11pt">&#9745;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman,serif; text-align: justify"><FONT STYLE="font-size: 11pt">No fee required.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic; font-size: 11pt">&#9744;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(1)</FONT></TD>
    <TD STYLE="width: 92%; font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Title of each class of securities to which transaction applies: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Aggregate number of securities to which transaction applies: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(4)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Proposed maximum aggregate value of transaction: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(5)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Total fee paid: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic; font-size: 11pt">&#9744;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Fee paid previously with preliminary materials: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-family: MS Gothic; font-size: 11pt">&#9744;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify"><FONT STYLE="font-family: Arial,sans-serif; font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(1)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Amount previously paid: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify"><FONT STYLE="font-family: Arial,sans-serif; font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(2)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Form, Schedule or Registration Statement No.: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify"><FONT STYLE="font-family: Arial,sans-serif; font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(3)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Filing Party: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Times New Roman,serif; text-align: justify"><FONT STYLE="font-family: Arial,sans-serif; font-size: 11pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">(4)</FONT></TD>
    <TD STYLE="font-family: Times New Roman,serif"><FONT STYLE="font-size: 11pt">Date Filed: </FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1, LLC, CCUR Holdings, Inc., CIDM II, LLC, Julian
D. Singer, and David S. Oros (collectively, &ldquo;<U>JDS1</U>&rdquo;), are filing this Schedule 14A with the U.S. Securities and Exchange
Commission (&ldquo;<U>SEC</U>&rdquo;) in connection with JDS1&rsquo;s plans to solicit proxies from the stockholders of Catalyst Biosciences,
Inc., a Delaware Corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the Company&rsquo;s 2022 Annual Meeting of Stockholders,
any special meeting held in lieu thereof, and at any and all adjournments or postponements thereof (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><B>Schedule 13D Amendment No. 7 Filed on February 28,
2022</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">On February 28, 2022, JDS1 filed Amendment No. 7 to
its Schedule 13D with respect to the Company (the &ldquo;<U>Schedule 13D/A</U>&rdquo;). The following disclosure was included in Item
4 of the Schedule 13D/A and is being included in this Schedule 14A because such disclosure may be deemed&nbsp;to be solicitation material
in connection with JDS1&rsquo;s plans to solicit proxies from the Company&rsquo;s stockholders for use at the 2022 Annual Meeting:</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in; background-color: white"><I>&ldquo;As
previously disclosed, for the past few months, JDS1 has privately engaged with members of the Issuer&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
regarding its composition and JDS1&rsquo;s concerns that, given the precipitous decline in the Issuer&rsquo;s stock price over the past
year, the Board is in urgent need of fresh shareholder representation. As of the close of business on February 25, 2022, the Issuer&rsquo;s
stock closed at a price of $0.60 per share, which represented an approximately 90% decline from the Issuer&rsquo;s closing stock price
of $6.03 per share on February 26, 2021. In addition, the Issuer&rsquo;s stock has spent more than 30 consecutive trading days below $1.00,
the latter condition subjecting the Issuer to the risk of being delisted by Nasdaq. </I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in; background-color: white"><I>As also
previously disclosed, given the Issuer&rsquo;s rapidly approaching deadline for shareholders to submit advance notices of shareholder
nominations and other business proposals, and the absence of any indication that the Issuer is prepared to extend its advance notice deadline
as a sign of good faith, JDS1 is currently planning to nominate three highly qualified and experienced candidates to replace the three
members of the Board who are standing for election at the Issuer&rsquo;s 2022 Annual Meeting of Stockholders (the &ldquo;<U>2022 Annual
Meeting</U>&rdquo;) and submit a non-binding proposal calling for the Board to take the steps necessary to declassify itself (in a manner
that does not affect the unexpired terms of the previously elected directors) and have all directors stand for election each year. </I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in; background-color: white"><I>As JDS1
continues to take the necessary steps to prepare for a potential proxy contest in connection with the 2022 Annual Meeting, it intends
to continue to engage in discussions with the Board and/or management relating to not only its concerns with the Issuer&rsquo;s board
composition, sub-standard corporate governance, plans for maximizing shareholder value, and the need to make the Board more accountable
to shareholders, but also possible constructive paths for avoiding a costly proxy contest.&rdquo;</I></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 8pt"><B>Important Additional Information and Certain Information Concerning the
Participants</B></P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1 intends to file a preliminary proxy statement
and accompanying proxy card with the SEC to be used to solicit proxies from the Company&rsquo;s stockholders in connection with the 2022
Annual Meeting to have stockholders elect three director nominees to the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
and approve a non-binding proposal requesting that the Board take the necessary steps to declassify the Board (in a manner that does not
affect the unexpired terms of the previously elected directors) so that all directors are elected on an annual basis commencing at the
next annual meeting of stockholders after the 2022 Annual Meeting.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">JDS1 STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY
TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY
MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT&nbsp;<U>HTTPS://WWW.SEC.GOV</U>.</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">The participants in the proxy solicitation are anticipated
to be JDS1, LLC, a Delaware limited liability company, CCUR Holdings, Inc., a Delaware corporation, CIDM II, LLC, a Delaware limited liability
company, Julian D. Singer, David S. Oros, and JDS1&rsquo;s nominees. As of the date hereof, JDS1 has not yet finalized its slate of director
nominees who will stand for election at the 2022 Annual Meeting. Once JDS1 finalizes its slate of director nominees who will stand for
election at the 2022 Annual Meeting, such individuals shall be named and appropriate participant disclosures shall be made with respect
to each such individual.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">As of the date hereof, JDS1, LLC directly beneficially
owns 780,432 shares of Common Stock, par value $0.001 per share, of the Company (the &ldquo;<U>Common Stock</U>&rdquo;), including 500
shares of Common Stock held in record name. As of the date hereof, CCUR Holdings, Inc. directly beneficially owns 532,100 shares of Common
Stock. JDS1, LLC, as an affiliate of CCUR Holdings, Inc., may also be deemed to be the beneficial owner of the 532,100 shares of Common
Stock held by CCUR Holdings, Inc. As of the date hereof, CIDM II, LLC does not directly own any shares of Common Stock, but, as the asset
manager to CCUR Holdings, Inc., may be deemed the beneficial owner of the 532,100 shares of Common Stock beneficially owned by CCUR Holdings,
Inc. As of the date hereof, Mr. Singer does not directly own any shares of Common Stock, but may be deemed to have beneficial ownership
of the Common Stock as a result of being the managing member of each of JDS1 and CIDM II, LLC and an affiliate of CCUR Holdings, Inc.
Accordingly, Mr. Singer may be deemed to beneficially own (i) the 780,432 shares of Common Stock directly beneficially owned by JDS1,
LLC, and (ii) the 532,100 shares of Common Stock directly beneficially owned by CCUR Holdings, Inc. As of the date hereof, Mr. Oros directly
beneficially owns 338,600 shares of Common Stock.</P>

<P STYLE="font: 11pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
